Fesoterodinefumarate

Bezeichnung:Fesoterodinefumarate

CAS-Nr286930-03-8

Englisch Name:Fesoterodinefumarate

CBNumberCB51075581

SummenformelC30H41NO7

Molgewicht527.65

MOL-Datei286930-03-8.mol

Fesoterodinefumarate physikalisch-chemischer Eigenschaften

Schmelzpunkt	72-78°C
storage temp.	Inert atmosphere,2-8°C
Löslichkeit	DMSO (Slightly), Ethanol (Slightly), Methanol (Slightly)
Aggregatzustand	Solid
Farbe	White to Off-White
Wasserlöslichkeit	H2O: 2mg/mL, clear
Stabilität	Hygroscopic

Gefahreninformationscode (GHS)

Fesoterodinefumarate Chemische Eigenschaften,Einsatz,Produktion Methoden

Chemische Eigenschaften
White Solid
Verwenden
(R)-Fesoterodine Fumarate is a muscarinic receptor antagonist for the treatment of Lower Urininary Tract Symptoms (LUTS). It is very similar to Tolterodine (T535800).
Verwenden
Fesoterodine fumarate (Toviaz) is an antimuscarinic agent and is rapidly de-esterified to its active metabolite 5-hydroxymethyl tolterodine that is a muscarinic receptor antagonist. Fesoterodine fumarate (Toviaz) is used to treat the symptoms of overactiv
Clinical Use
Antimuscarinic:
Symptomatic treatment of urinary incontinence, frequency or urgency
Arzneimittelwechselwirkung
Potentially hazardous interactions with other drugs
Anti-arrhythmics: increased risk of antimuscarinic side effects with disopyramide.
Antifungals: dose reduction advised with itraconazole and ketoconazole.
Antivirals: dose reduction advised with atazanavir, indinavir, ritonavir and saquinavir.
Induction of CYP3A4 may lead to subtherapeutic plasma levels. Concomitant use with CYP3A4 inducers (e.g. carbamazepine, rifampicin, phenobarbital, phenytoin, St John's Wort) is not recommended.
Co-administration of a potent CYP2D6 inhibitor may result in increased exposure and adverse events. A dose reduction to 4 mg may be needed'
Stoffwechsel
Rapidly and extensively hydrolysed to its active metabolite. The active metabolite is further metabolised in the liver to its carboxy, carboxy-N-desisopropyl, and N-desisopropyl metabolites via two major pathways involving CYP2D6 and CYP3A4. None of these metabolites contribute significantly to the antimuscarinic activity of fesoterodine. Approximately 70% of an oral dose of fesoterodine is recovered in the urine as metabolites, and a smaller amount in the faeces.

Fesoterodinefumarate Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

286930-03-8, Fesoterodinefumarate Verwandte Suche:

Send Inquriy